{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:18:25Z","timestamp":1792657105691,"version":"4.5.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Palmoplantar psoriasis is a frequently encountered variant of psoriasis. It is difficult to treat and even more difficult to maintain remission as it is exacerbated by friction and trauma of the patient's daily activities. Existing topical modalities of treatment are often inadequate and show unpredictable response.\n                    <jats:bold>Aim:<\/jats:bold>\n                    To study the efficacy and safety of a newer retinoid, tazarotene, as 0.1% cream in the treatment of palmoplantar psoriasis.\n                    <jats:bold>Materials and Methods:<\/jats:bold>\n                    Thirty adult patients with palmo-plantar psoriasis were randomized to therapy with once daily application of topical tazarotene cream (0.1%) or once daily application of clobetasol propionate cream (0.05%) for 12 weeks. The patients were assessed every 2 weeks for improvement in Erythema, Scaling, Fissures and Induration (ESFI) score and Physicians Global Assessment Scale.\n                    <jats:bold>Results:<\/jats:bold>\n                    At 12 weeks, the tazarotene group showed mean ESFI reduction to 1.12 (83.2%) from 6.65 at baseline. Complete clearance was noted in 52.9% of the patients. Clobetasol propionate group showed mean ESFI reduction to 0.62 (89.1%) from 5.69 at baseline, with complete clearance in 61.5% of the patients. Differences between the two groups were statistically insignificant. Side effects observed were initial irritation (41%) in the tazarotene group and hypopigmentation (53.8%) in the steroid-treated patients.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Tazarotene is as effective as clobetasol propionate and provides a good alternative for the treatment of palmo-plantar psoriasis where hypopigmentation limits the use of clobetasol propionate cream.\n                  <\/jats:p>","DOI":"10.4103\/0019-5154.77550","type":"journal-article","created":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T01:04:45Z","timestamp":1299805485000},"page":"40-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["EVALUATION OF TOPICAL 0.1% TAZAROTENE CREAM IN THE TREATMENT OF PALMOPLANTAR PSORIASIS: AN OBSERVER-BLINDED RANDOMIZED CONTROLLED STUDY"],"prefix":"10.4103","volume":"56","author":[{"given":"Bijal H","family":"Mehta","sequence":"first","affiliation":[{"name":"Minal Specialised Clinic Dermatology, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta T","family":"Amladi","sequence":"additional","affiliation":[{"name":"Kaya Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1067\/mjd.2000.108319","article-title":"Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid","volume":"43","author":"Lebwohl","journal-title":"J Am Acad Dermatol 2000"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-4362.2001.01167.x","article-title":"Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis","volume":"40","author":"Koo","year":"2000","journal-title":"Int J Dermatol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0378-6323.30663","article-title":"Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study","volume":"73","author":"Angelo","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1346-8138.2004.tb00602.x","article-title":"Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis","volume":"31","author":"Kumar","year":"2004","journal-title":"J Dermatol"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0190-9622(00)90225-1","article-title":"Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel","volume":"42","author":"Behrens","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"S54","key":"R6-20260605","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1365-2133.1999.140S54008.x","article-title":"Optimising therapy: tazarotene in combination with phototherapy","volume":"140","author":"Lowe","year":"1999","journal-title":"Br J Dermatol"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1046\/j.1365-2133.2000.03900.x","article-title":"Calcipotriol versus tazarotene as combination therapy with narrow band ultraviolet B(311nm): efficacy in patients with severe psoriasis","volume":"143","author":"Schiener","year":"2000","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201156010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:09:30Z","timestamp":1787756970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201156010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-5154.77550","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2009-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}